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Abstract
Candida albicans causes superficial to systemic infections in immuno-compromised individuals. The concomitant use of
fungistatic drugs and the lack of cidal drugs frequently result in strains that could withstand commonly used antifungals,
and display multidrug resistance (MDR). In search of novel fungicidals, in this study, we have explored a plant alkaloid
berberine (BER) for its antifungal potential. For this, we screened an in-house transcription factor (TF) mutant library of C.
albicans strains towards their susceptibility to BER. Our screen of TF mutant strains identified a heat shock factor (HSF1),
which has a central role in thermal adaptation, to be most responsive to BER treatment. Interestingly, HSF1 mutant was not
only highly susceptible to BER but also displayed collateral susceptibility towards drugs targeting cell wall (CW) and
ergosterol biosynthesis. Notably, BER treatment alone could affect the CW integrity as was evident from the growth
retardation of MAP kinase and calcineurin pathway null mutant strains and transmission electron microscopy. However,
unlike BER, HSF1 effect on CW appeared to be independent of MAP kinase and Calcineurin pathway genes. Additionally,
unlike hsf1 null strain, BER treatment of Candida cells resulted in dysfunctional mitochondria, which was evident from its
slow growth in non-fermentative carbon source and poor labeling with mitochondrial membrane potential sensitive probe.
This phenotype was reinforced with an enhanced ROS levels coinciding with the up-regulated oxidative stress genes in BER-
treated cells. Together, our study not only describes the molecular mechanism of BER fungicidal activity but also unravels a
new role of evolutionary conserved HSF1, in MDR of Candida.
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Introduction
Candida albicans is a part of normal commensal flora of human
body, which becomes one of the most resilient fungal pathogen
under low host immunity [1], [2]. Available antifungals predom-
inantly include azoles, echinocandins, polyenes and allylamines
[3]. Each of these classes of antifungals have a distinct mode of
action, for example azoles target heme protein, cytochrome P450
lanosterol 14 a demethylase thereby impeding conversion of
lanosterol to fecosterol and subsequently blocking ergosterol
biosynthesis [4]. Echinocandins interfere with CW synthesis by
inhibiting b1-3 glucan synthase [5]. Polyenes have affinity to bind
membrane sterols that results in the formation of aqueous pores
ensuing the leakage of crucial cellular components and subsequent
cell death [6]. Allylamines are relatively newer class of antifungal
that also inhibit ergosterol biosynthesis but by specifically targeting
squalene epoxidase [7].
Notwithstanding the fact that some pathogenic Candida species
are intrinsically resistant to antifungals, prolonged use of drugs also
leads to an emergence of multidrug resistant (MDR) strains posing
additional clinical challenges [8]. Because of the limited arsenal of
antifungals, there is constant need to find new antifungals with
novel targets. In this context, herbal antifungals have acquired
significance owing to their natural origin [9–11]. Besides herbal
compounds there are innumerable non-herbal chemical com-
pounds with antifungal potentials. For example, gentian violet has
been used to treat recurrent vulvovaginal candidosis [12].
Idarubicin, a DNA topoisomerase inhibitor is effective against
Aspergillus niger, Cryptoccocus neoformans and C. glabrata [13],
caffeine exhibits antifungal potential by interfering with MAPK
signaling and CW integrity pathway [14]. Recently, our group has
shown that a bacteriological stain malachite green (MG) exerts
antifungal effect by shifting the metabolic flux of Candida cells
towards fermentation, increasing generation of ROS and leading
to cell necrosis [15].
Isoquinoline alkaloid berberine (BER), which is bright yellow
colored, is widely used for dyeing wool, leather and wood. BER is
shown to elicit anticancerous, antidiabetic, anti atherosclerotic and
neuroprotective properties. Additionally, BER also exhibits
antibacterial, and has also shown anti-inflammatory potentials
[16], [17]. Although there are instances where BER is shown to
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elicit antifungal activity against C. albicans and C. glabrata [18],
how it exerts its effect is not understood.
In the present study, we attempted to elucidate the antifungal
effect of BER on C. albicans and non-albicans species. For this, we
screened the transcriptional factor (TF) mutants in house library of
C. albicans and identified a mutant of heat shock factor (HSF1)
that was hypersusceptible to BER [19]. HSF1 activates transcrip-
tion via heat shock element (HSE) in response to thermal
adaptation. Our study provides evidence that the treatment of
Candida cells with BER compromises CW integrity via the
calcineurin pathway leading to cell death. The study also assigns a
new role to HSF1 in combating MDR.
Material and Methods
Strains and Media
All the media components were purchased from HiMedia
(Mumbai, India). BER, 29, 79 -dichlorofluorescein diacetate
(DCFDA), and glycerol were purchased from Sigma chemicals
Co. (St. Louis, MO). Ascorbic acid (AA) was purchased from SRL
(Mumbai, India). Ranbaxy, India generously provided FLC.
AMB, CAS, CR, CFW, SDS, TRB were purchased from Sigma
chemicals Co. (St. Louis, MO) Superscript-II Reverse transcriptase
enzyme, oligo dt(18)primer and random primer from Invitrogen,
USA. dATP, dGTP, dTTP and dCTP were bought from Sigma.
All the yeast strains were grown in yeast-extract peptone dextrose
(YPD) agar and incubated at 30uC. All the strains were stored as
15% glycerol stocks in 280uC storage which were freshly revived
on YPD before beginning of the experiment. Details of all the
strains used in the study is described in table S1 in File S1.
Growth curve and serial dilution assays
Freshly revived C. albicans strains were inoculated at 0.1 OD600
in YPD in four different tubes. BER was added at 100, 150,
200 mg/ml in three of the tubes while no BER was added to the
control tube. Cells were allowed to grow at 30uC at 200 rpm. 1 ml
of culture is withdrawn from each tube at interval of 4 hours and
absorbance is taken at 600 nm. Serial dilution assays were done in
both liquid and solid YPD medium for testing the drug
susceptibility essentially by following the guidelines provided by
CLSI (Clinical and Laboratory Standards Institute) [20],[21].
Concentration of each drug used in the study is provided in
parenthesis BER (200 mg/ml, 300 mg/ml depending on the WT
strain used), doxycyclin (DOX; 0.6 mg/ml), caspofugin (CAS;
.05 mg/ml), amphotericin B (AMB; 4 mg/ml), calcofluor white
(CFW; 60 mg/ml), congo red (CR; 150 mg/ml), SDS (0.05%),
ascorbic acid (AA; 0.3 mg/ml).
Screening of TF mutant library for BER susceptibility
We have employed an in-house TF mutant library containing
240 homozygous mutant strains individually deleted for genes with
DBD (DNA binding domain) by UAU transposition (,70%) or by
URA blaster technique or by PCR product recombination PCR
[15]. The TF mutants were subjected to the screening for BER
susceptibility using serial dilution assays as described above. This
was done thrice and the TF mutant strain that was reproducibly
susceptible to BER was tested in the final screen.
Figure 1. Antifungal potential of BER (a) Growth curve of WT C. albicans cells at 100, 150 and 200 mg/ml, (b) serial dilution assays in
solid (left panel) and liquid medium for testing BER susceptibility of C. albicans and non albicans species. (c) Serial dilution assays of
CDR1 (Gu5) and MDR1 (F5) overexpressing and (d) their deletions strains in presence of BER.
doi:10.1371/journal.pone.0104554.g001
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End point comparative reverse transcription PCR (RTPCR)
RNA was extracted using RNeasy mini kit Qiagen essentially by
following their protocol. RNA is quantitated by NanoDrop 2000
UV-Vis spectrophotometer from Thermo Scientific. 1 mg/ml of
DNase treated RNA was taken further for cDNA preparation
using RevertAid H Minus Reverse Transcriptase kit from Thermo
Scientific using protocol provided by the manufacturer. 1 ml of the
cDNA product was used for amplification using Taq DNA
polymerase from New England Biolabs in a total reaction volume
of 50 ml. Primers used for the amplification of target genes are
listed in table S2 in File S1.
Transmission electron microscopy (TEM)
TEM was performed to examine the effect of BER on the cell
wall of HSF1tet/hsf1D strain in comparison with the WT as
described elsewhere [22]. Cells were grown to mid-exponential
phase and treated with DOX, BER or BER +DOX. The cells
were washed with PBS buffer to remove the media and then cells
were chemically fixed using 2% glutaraldehyde at 4uC for 2 hours
followed by 0.5% osmium tetroxide. The cells were finally
embedded in epon resin. The samples were visualized by TE
microscope by Jeol JEM-2100F, Tokyo Japan.
BER transport
BER transport inside the cells was measured exploiting its
fluorescence. BER has excitation wavelength of 405 nm and
emission is at 520 nm [23]. Late stage cells were washed with PBS
twice and the cells were resuspended in PBS to 0.1 OD600. Cells
were incubated for 1 hour and then washed cells were resus-
pended in PBS with 2% glucose with BER (MIC50 concentration).
Fluorescence detection in cells was carried out with a Fluorescence
Activated Cell Sorter (FACS) caliber flow cytometer (Becton-
Dickinson Immunocytometry Systems, San Jose, CA) at FL-1. Ten
thousand events were counted and fluorescence intensity was
compared between untreated cells and BER-treated cells using
Cell Quest software.
Measurement of ROS (Reactive Oxygen Species)
generation
Endogenous ROS generation was measured using DCFDA
(29,79-Dichlorofluorescin diacetate) which is an oxidant sensitive
fluorescent probe [24]. The method employed is previously
described in details [15]. Briefly, wild type cells were inoculated
in YPD broth at 0.1 OD600 and allowed to incubate at 30uC until
the OD600 reaches 0.8. BER (MIC50) was added to the cells and
same volume of mock in the control then allowed to grow further
for 80 min. We used antioxidant AA for reversal of generation of
ROS. Cells were pretreated with 5 mM AA 60–90 min and then
incubated in presence of BER for 80 mins after washing the cells,
10 mM DCFDA was added. Cells were then kept at 30uC for
30 min. Fluorescence was measured (Excitation and emission at
488 nm and 540 nm respectively) and quantified by FACS as
mentioned above.
Evaluation of induction of apoptosis by BER treatment
Cells undergoing apoptosis was determined by the externaliza-
tion of PS (phosphatidylserine), an apoptotic marker, by using
FITC (Fluorescein isothiocyanate) labeled Annexin V kit (FITC
Annexin V Apoptosis Detection Kit I, BD Biosciences). Exponen-
tially growing cells were treated with BER (at MIC80; 200 mg/ml).
Figure 2. TF mutant library screening (a) Serial dilution assays of TF mutant strains in the presence of BER, (b) end point
comparative RTPCR of HSF1 (gene deleted in JMR044) in WT strain (DAY286) in presence and absence of BER.
doi:10.1371/journal.pone.0104554.g002
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Cells were then treated with zymolyase to obtain spheroplasts,
which were incubated with FITC Annexin V and PI (propidium
iodide). The fluorescent signal was assessed using a Fluorescence
Activated Cell Sorter (FACS) caliber flow cytometer (Becton-
Dickinson Immunocytometry Systems, San Jose, CA). We used
488 nm excitation and a 515 nm band pass filter for FITC
detection and a filter .560 nm for PI detection. A total of 10,000
events were counted at the flow rate. Data analysis was performed
using Cell Quest software. Cells labeled with FITC indicate onset
of apoptosis while those with PI label predominantly show the
presence of necrotic cells (AnnV/PI) [15].
Determination of active mitochondria using MitoTracker
Exponentially growing cells were treated with BER (MIC50), for
80 min washed and resuspended in YPD and treated with 200 nM
of MitoTracker Deep Red FM (MTR-FM) [25]. The cells were
allowed to incubate for 30–45 min at 30uC with 200 rpm. The
cells were washed and resuspended in 400 mL of PBS fluorescence
is measured by FACS analysis as described above. MTR-FM has
excitation and emission spectra of 644 nm and 665 nm respec-
tively.
Results
Antifungal potential of BER does not depend on major
efflux pump proteins
For an in depth analysis of mechanism of action of antifungal
potentials of an herbal alkaloid BER, we have examined the
growth pattern of C. albicans and observed that BER maximally
retarded cell growth at 200 mg/ml (Figure 1(a)). In serial dilution
assays, BER at 200 mg/ml was also effective against all the tested
non-albicans species with variable susceptibilities (Figure 1(b)). For
instance, C. utilis, C. kefyr and C. krusei were relatively
hypersusceptible to BER and their MIC50 ranged between
25 mg/ml and .50 mg/ml, while C. glabrata and C. tropicalis
were the least susceptible species with MIC50 of 200 mg/ml in
contrast to C. albicans. Notably, BER has reported to be non-toxic
to human cells [26].
One of the predominant mechanisms to cope up with the
antifungal stress is an overexpression of drug efflux pump encoding
genes such as CDR1 and MDR1 belonging to the ABC (ATP
Binding Cassette) and MFS (Major Facilitators) super families of
transporters, respectively [27]. We assessed the implication of
these pump proteins in withstanding BER stress. For this, we used
azole-susceptible (AS) and azole-resistant (AR) clinical isolates
overexpressing these pump encoding genes [28], [29], and
examined the effect of BER. As depicted in Figure 1(c) and 1(d),
the susceptibility to BER in CDR1 or MDR1 overexpressing
strains was only modestly affected as compared with susceptible
strains. The possibility that the observed modest increase in
susceptibility of clinical resistant isolates towards tested drugs
might arise due to acquired mutations in other genes, that can also
not be ruled out. To check the specific roles of these transporters,
we have used strains that were individually disrupted for these
genes but the susceptibility in these nulls (DSY449 and SFluM4A)
remained unaffected in comparison to the respective WT strains.
Together, these results imply that efflux pumps do not impact
BER activity (Figure 1 (c) and 1(d)).
Figure 3. HSF1 conditional mutant is susceptible to various antifungal drugs (a) susceptibility WT, HSF1 conditional mutant and
HSF1 heterozygous for BER (b) different classes of antifungal drugs; FLC, CAS, TRB, AMB, and their combination with BER, (c) CW
perturbing agents; CFW, CR, SDS (d) TEM images of WT, HSF1 conditional mutant and HSF1 heterozygous in presence of BER.
doi:10.1371/journal.pone.0104554.g003
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HSF1 levels affect susceptibility to BER and collateral
susceptibilities to other drugs
To understand the mechanism behind susceptibility to BER, we
carried out a screen of an in-house library of TF mutant strains of
C. albicans [15]. There are ,275 genes that contains DBD in C.
albicans these genes were deleted individually as explained in
materials and methods section. All the strains that appear
reproducibly (in triplicate) susceptible were subjected to a final
screen as shown in Figure 2(a). Among all the TFs, HSF1, a heat
shock factor mutant (JMR044) was most susceptible to BER
treatment (MIC50 25 mg/ml) in comparison with WT strain
(DAY286) (MIC50 100 mg/ml) (figure S1 in File S1). End point
comparative RTPCR revealed a slight increase in the expression
of HSF1 after BER treatment in C. albicans, thus implying a
direct effect of BER on its expression (Figure 2(b)).
HSF1 is an essential gene and it could be likely that this TF
mutant that was generated by UAU transposition could still
exhibit HSF1 activity due to the chosen disruption method [19],
[30]. To reconfirm HSF1 impact on MDR, we employed a
conditional HSF1 mutant (hsf1D/tet-HSF1) in which HSF1
expression is under control of the TET promoter [19]. We tested
the susceptibility of the HSF1 conditional mutant in presence of
TET analogue, DOX, which shuts off the expression of HSF1.
The results mirrored the BER susceptibility phenotype that was
observed with the mutant strain JMR044 of TF library screen
(Figure 3(a)). We also verified whether conditional mutant hsf1D/
tet-HSF1 was collaterally affecting susceptibility to other drugs.
FLC, AMB, TRB, and CAS (caspofungin). Additionally, we have
also evaluated the effect of combination of BER and these drugs
on conditional mutant hsf1D/tet-HSF1. Interestingly, the condi-
tional HSF1 mutant was highly susceptible towards different
classes of antifungal drugs including FLC, AMB, TRB, and CAS
(caspofungin) (Figure 3(b)). Our susceptibility assays revealed that
hsf1D/tet-HSF1 not only displayed enhanced susceptibility to BER
but also to drugs acting on membrane ergosterol (TRB, FLC,
AMB) or inhibit CW synthesis (CAS) (Figure 3(b)) [31], [32].
However, combination of BER and above mentioned drugs did
not seem to enhance the susceptibility of HSF1 conditional
mutant (Figure 3(b)). This highlights that the effects of BER and
HSF1 leading to drug susceptibility are manifested by indepen-
dent circuitry. The impact of HSF1 on drug susceptibilities
appeared to be independent of known attributes of MDR [33],
[34]. For example, the expression of CDR1, CDR2, MDR1,
ERG11, TAC1, UPC2 did not change in the HSF1 conditional
mutant in presence and absence of BER (figure S2 in File S1).
Susceptibility of hsf1D/tet-HSF1 towards ergosterol and CW
synthesis inhibitors led us to evaluate specific effect of CW
perturbing agents such as SDS (sodium dodecyl sulphate), CR
(congo red) and CFW (calcofluor white) [35] on this mutant. We
performed serial dilution assays in the presence of these CW
perturbing agents. As evident from Figure 3(c), hsf1D/tet-HSF1
was susceptible to SDS (0.05%), CR (150 mg/ml) and CFW
(60 mg/ml). The impact of HSF1 on CW was reinforced by TEM
of hsf1D/tet-HSF1 strains. One could visualize in TEM pictures,
the damage to the CW of hsf1D/tet-HSF1 strains. When hsf1D/tet-
HSF1 strains were treated with BER, the impact appeared to be
more aggravated as was evident from the rupturing of the CW and
shrinkage of the cytoplasm of hsf1D/HSF1 cells after BER
treatment (Figure 3(d)). Interestingly, the damage to CW as
revealed by TEM picture analyses following BER treatment was
not as severe as compared to untreated hsf1D/HSF1 cells
(Figure 3(d)).
BER affects CW integrity independent of HSF1
Taking clue from hsf1D/tet-HSF1, which was susceptible to CW
inhibitors, we explored whether the genes involved in the CW
integrity pathway were affected in BER-treated cells [36]. By
employing liquid assay according to the CLSI protocol, we
compared BER MICs in mutant strains for the genes involved in
heat shock (HSP90), calcineurin (CNA1, CNA2, CRZ1), and
MAP kinase pathways (BCK1, MKC1). As evident from the assay,
calcineurin (crz1D/crz1D, cna1D/cna1D) and MAP kinase path-
ways (bck1D/bck1D) mutants were more susceptible to BER
treatment with MIC50 of 25 mg/ml as compared to wild type
Figure 4. Effect of BER on CW integrity mutants (a) serial dilution assay of calcineurin and MAP kinase pathway and HSP90 gene
deleted to evaluate BER MIC50, (b) end point comparative RTPCR of genes involved in CW integrity in WT C. albicans cells in
presence and absence of BER, (c) and in HSF1 conditional mutant lane indicates 1: WT, 2: HSF1 TET/hsf1, 3: HSF1/hsf1, 4,5,6,: +Doxy,
7,8,9 :+BER, 10, 11, 12: +Doxy+Ber.
doi:10.1371/journal.pone.0104554.g004
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(100 mg/ml) (Figure 4(a)). End point comparative RTPCR con-
firmed that the expression of genes involved in these pathways
(including CRZ1, CNA1 and BCK1) was increased upon BER
treatment (Figure 4(b)). Notably, depletion of HSF1 levels did not
arrest the increased expression of these genes upon BER treatment
(Figure 4(c)) in combination of DOX indicating BER effect on
these genes is independent of HSF1.
BER treatment results in mitochondrial dysfunction
To assess functional mitochondria, we compared the growth of
BER treated cells in non-fermentative and in fermentative carbon
sources and compared it with the growth of untreated cells. We
observed that, even at non-lethal BER concentration (below
MIC50; 75 mg/ml), cells were unable to grow when non-
fermentable glycerol was provided as sole carbon source
(Figure 5(a)). We addressed the mitochondrial activity by employ-
ing MTR-FM probe [25]. MTR-FM probe is known to passively
diffuse across yeast cell membrane and to accumulate in active
mitochondria, which can be visualized by enhanced fluorescence.
Using flow cytometry depicted in Figure 5(b) BER-treated cells
showed poor fluorescence intensity as compared to untreated cells.
Together, poor growth in non-fermentable carbon source and
decrease in MTR-FM fluorescence reinforced dysfunctional
mitochondria following BER treatment. Notably, HSF1 condi-
tional mutant did not show any impact on mitochondrial
functional status (Figure 5 (c))
Determination of generation of ROS and apoptosis on
BER treatment
Mitochondrial dysfunction on BER treatment led us to
determine the status of ROS in presence of BER. To measure
the changes in ROS generation we exploited a fluorescent
molecule chloromethyl-dichlorodihydrofluorescein diacetate
(CM-H2DCFDA), which can readily enter into the cells and is
sensitive to redox changes [24]. It is deacetylated by endogenous
esterase into dichlorofluorescein, which fluoresces on oxidation by
Figure 5. BER treatment results in dysfunctional mitochondria (a) growth of C. albicans cells in non-fermentable carbon source
(glycerol) in presence of BER (b) MTR labeling of the active mitochondria by FACS in C. albicansWT cells in presence and absence of
BER, bar graph representing number of events gated (c) MTR labeling were also done in WT, HSF1 conditional mutant and HSF1
heterozygous strains in presence and absence of BER.
doi:10.1371/journal.pone.0104554.g005
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ROS. Wild type cells treated with a MIC50 concentration of BER
(100 mg/ml) were allowed to incubate in presence of 10 mM of
CM-H2DCFDA. As shown in Figure 6, fluorescence increased
after BER treatment indicating generation ROS. The increase in
ROS following BER treatment could be partially reversed by the
addition of antioxidant such as AA [37]. This implied that BER
treatment results in production of ROS, which could contribute to
the antifungal effect exerted by BER.
To estimate whether generation of ROS leads to apoptosis on
BER treatment, we checked for externalization of phosphatidyl
serine (PS), a marker for apoptotic cells. Annexin V (Annexin V
Apoptosis Detection Kit I, BD Biosciences) binds to PS which is in
turn linked to FITC hence can be detected through Flow
Figure 6. Determination of endogenous ROS generation by BER and induction of apoptosis (a) (upper panel) bar graph
representing relative fluorescent units when cells were treated with DCFDA in presence and absence of BER, AA is added to revert
the ROS production, (lower panel) fluorescent microscopy images of WT C. albicans cells labeled with DCFDA, (b) Cytometric
determination FITC Annexin V labeling in WT cells treated with BER.
doi:10.1371/journal.pone.0104554.g006
Figure 7. Model depicting pathways affected by BER treatment in C. albicans.
doi:10.1371/journal.pone.0104554.g007
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cytometry as explained in material and methods. However, there
was no significant change in the population of cells showing FITC
labeling on treatment with BER at MIC80 as seen in Figure 6(b).
For example, our data show that the percentage of gated cells
labeled with Annexin V-FITC did not change significantly as it
ranged between 0.67% in WT strain to 0.86% in cells treated with
BER. This excluded the possibility that BER at MIC80 does not
trigger apoptosis in C. albicans cells.
Discussion
In this study, we show that the plant alkaloid BER displays
potential anti-Candida activity which has been earlier reported to
be non-toxic to humans [26] Our data supports that HSF1, a
transcription regulator that is an essential gene involved in thermal
adaptation of Candida cells, impacts BER susceptibility of C.
albicans cells. HSF1 protects cells from thermal assault by
activating the expression of HSPs (Heat Shock Proteins) that act
as chaperones to rescue proteins from misfolding under duress
[19]. Our observation suggests that HSF1, which not only impacts
BER susceptibility, also influences susceptibility of Candida cells to
different drugs with distinct targets. Thus HSF1 mutant is also
observed to be collaterally susceptible to other drugs (Figure 3(b)).
However, the impact of BER and HSF1 on drug susceptibility is
manifested by independent pathways in Candida cells. Our
conclusions are based upon the following supporting observations.
The treatment of TF mutant strains of Candida cells with BER
revealed that HSF1 mutant was most susceptible to this antifungal
compound. BER treatment affects the calcineurin pathway and
CW integrity leading to dysfunctional mitochondria and cell
death. HSF1 levels also impact CW integrity, which is apparent
from the susceptibility of HSF1 conditional mutants towards CW
inhibitors and from disrupted CW visualized under TEM images.
However, unlike BER treatment, the impact of HSF1 on CW
integrity was independent of calcineurin stress pathway. For
example, neither HSF1 levels could affect the expression of
calcineurin pathway genes nor observed dysfunctional mitochon-
dria and enhanced ROS levels following BER treatment were
associated with HSF1 phenotype. Although, HSF1 levels poten-
tiate the antifungal activity of BER but its influence in enhancing
drug susceptibility adopts different regulatory circuitry as shown in
Figure 7. Together, our results show that BER displays its
antifungal potential through its ability to impair mitochondrial
function, generation of ROS, targeting CW integrity pathway and
also affecting heat shock transcription factor HSF1.
BER has been touted as potential anticancerous agent as it
generates ROS and induces apoptosis in human prostrate cancer
cells [38], however, our Annexin V labeling data rules out any
induction of apoptosis in C. albicans following BER treatment
(Figure 6(b)). Implication of BER in dysfunction of mitochondria
in HSC-3 oral cancer cells has also been studied [39]. Another
report shows that it is accumulated inside mitochondria, which
results in the arrest of cell proliferation, mitochondrial fragmen-
tation, along with depolarization and oxidative stress in K1735-
M2 mouse melanoma cells [40]. Considering evidences from other
systems, the possibility of other pathways, which may also govern
BER susceptibility, could not be excluded.
Several major mechanisms of MDR have been identified.
However, recent studies reveal newer regulatory pathways that
govern the development of MDR in Candida cells. For instance,
the ‘two component system’ composed of a membrane-bound,
sensor histidine kinase (HK) protein, a cytoplasmic response
regulator (RR) and an intermediate histidine phosphotransfer
(HPt) protein. The two-component signal transduction pathways
which help to adapt yeast cells to environmental stress is also
shown to impact drug susceptibility of Candida cells [41]. The
depletion of cellular iron pools leads to decrease resistance to
several drugs involving ergosterol metabolism and calcineurin
dependent core stress response pathways [42]. The role of
mitochondria in MDR of C. glabrata is well documented [43].
Recently, electron transport defective null mutants of goa1 and
ndh51 of C. albicans were shown to display increased susceptibility
towards FLC [44]. Overwhelming emerging evidences also suggest
an intricate relationship between membrane lipids and MDR
wherein any compositional imbalance considerably influences
drug susceptibility of Candida cells [45], [46]. Similarly, CZF1, a
TF hitherto known to be responsible for white/opaque switching,
was identified from whole genome RNA-Seq as another mediator
the acquisition of MDR [47].
In the perspective of uncovering unconventional drugs that
possess antifungal property, we had earlier shown that a chemical
dye malachite green (MG), which is commonly used in fish
industry as an antifungal, antiparasitic and antibacterial agent,
could effectively kill C. albicans and non-albicans species [15]. MG
owes its antifungal effect by shifting the metabolic flux towards
fermentation, ROS generation leading to cell necrosis and is
independent of known MDR mechanisms [15]. UPC2 and STP2
aid in tolerating MG stress of Candida cells [15]. In another study,
natural polyphenol, curcumin (CUR) was shown to be cidal to C.
albicans as well as to non-albicans species and display synergism
when combined with known antifungals. CUR treatment induces
ROS generation and an early apoptosis in C. albicans cells [11].
Together, the fungicidal effects of natural and synthetic
compounds not only provide a platform to improve therapeutic
strategies but also unravel novel regulatory circuitry that impacts
MDR in Candida. This also indicates the flexibility of C. albicans
cells to tolerate stress due to a variety of drugs with different targets
by adopting different regulatory routes. Our results highlight that
the development of tolerance towards antifungal drugs is a
multifactorial phenomena, and the combat against MDR still
remains a challenge.
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